Afrezza Inhalant Product

DRUG2 trials

Sponsors

Model Clinical Research LLC, Diabetes and Glandular Disease Clinic

Conditions

Type 2 Diabetes Treated With InsulinType2 Diabetes

Phase 3

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

CompletedNCT03324776

Model Clinical Research LLCType2 Diabetes

Start: 2017-10-16End: 2020-06-10Updated: 2024-06-26

Phase 4

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

Diabetes and Glandular Disease ClinicType 2 Diabetes Treated With Insulin

Start: 2019-02-27End: 2020-03-15Updated: 2020-01-30